Blockchain Registration Transaction Record

FDA-Approved Drug Boosts Immunotherapy for Rare Liver Cancer

University of Washington researchers find an FDA-approved drug could boost immunotherapy for rare liver cancer fibrolamellar carcinoma. Learn how this breakthrough may impact treatment options.

This discovery is significant because fibrolamellar carcinoma, a rare and aggressive liver cancer, has shown little response to checkpoint inhibitors, leaving patients with few treatment options. The repurposing of an already-approved drug could accelerate clinical adoption, offering a new lifeline to those affected. Moreover, the research may pave the way for similar strategies in other hard-to-treat cancers, potentially expanding the reach of immunotherapy. For investors and biotech companies like Calidi Biotherapeutics, this underscores the value of exploring combination therapies, while for patients and caregivers, it brings hope that existing medicines can be harnessed to fight previously untreatable tumors.